ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

ASCO Hematology

Hematologic Malignancy Highlights From ASCO 2017

Cancer Network presents exclusive coverage on cancers of the blood from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 26. We bring you expert interviews and reports on the latest trials and scientific advances that are changing the way these malignancies are managed and treated.

ASCO Hematology

This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.

The novel IDH2-inhibitor enasidenib was well tolerated and offered durable responses in a phase I trial of relapsed or refractory acute myeloid leukemia patients with an IDH2 mutation.

Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.

A fifth course of cytarabine chemotherapy resulted in improved overall and disease-free survival in pediatric patients with low-risk acute myeloid leukemia.

Researchers are making much-needed progress in developing treatments for patients with three rare malignancies: recurrent and refractory primary central nervous (CNS) system lymphoma, secondary CNS lymphoma, and primary vitreoretinal lymphoma.

This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.

Adjuvant radiotherapy for diffuse large B-cell lymphoma is unnecessary for elderly patients who have PET-negative bulky disease following immunochemotherapy.

Pages

Subscribe to ASCO Hematology on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.